Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by CreatingApeon Jun 16, 2021 1:13pm
118 Views
Post# 33395837

RE:RE:RE:Poking myself in the eye each day with TH

RE:RE:RE:Poking myself in the eye each day with THI wonder if Egrifta for Nash and a life saving novel cancer approach will sell more easily than a SUPER niche cosmetic drug or a seemingly last resort intravenous HIV treatment. And I wonder if having a marketing ace from Pfizer as our CEO now will help with that as well... yes I am being sarcastic the answer to both is obviously yes! I would honestly rather still be hearing people complain about the offering than droning on about the IR. (Although I know they are lacking there but clearly they are making steps in the right direction!) Things are moving nicely at Thera, but of coarse not as fast as we want. But what did our mothers tell us about what comes to those who wait? I have been seeing things lining up nicely at Thera for a while. And if either cancer or NASH are a success we will be trading millions of shares a day, every day. Retail investors will know about it. And we here will all be very, very happy. Also dont forget that Thera has a GREAT track record of getting drugs approved. Find solace in that and be patient! Even just the fast track for cancer and moving straight to a phase 3 for nash is extremely impressive to say the least. Both of these indications will sell themselves if they reach approval! And with Paul behind the wheel it will be an absolute commercial slam dunk, even if only one of these works out. Mr. Spceo remember your own advice! Usually the moments of maximum pessimism of your clients is when things are about to turn around. The share price has reached a stable and mostly fair point for the existing business. And I know other companies are priced ridiculously. And today's market is crazy. But still in the end sanity and hard facts prevail! But we are on the precipice, and with positive data from either cancer or nash the SP is going to go on an absolute tear and we all know it.
<< Previous
Bullboard Posts
Next >>